---

Highlights of July 2019

1. Cipla eyes Chinese respiratory market through JV with Jiangsu Acebright.
2. Sun Pharma enters licensing agreement with China Medical System Holdings for the development and commercialization of its dermatology products.
3. Glenmark, Torrent Pharma ink licensing pact to co-market diabetes drug in India.
4. Strides forms JV with Sihuan Pharma to enter into Chinese market. Strides will license four products immediately to this JV with an option to expand the portfolio subsequently.
5. Italian pharma Zambon takes in Breath Therapeutics through US$558.7 Million deal.
6. Boehringer acquires AMAL Therapeutics for US$366 Million.
7. Altimmune to buy Presidio Partners portfolio firm Spitfire Pharma in a deal valued at around US$93 Million.
8. Boehringer grabs Yuhan’s NASH prospect in US$870 Million biobucks deal.
9. Ligand Pharmaceuticals Buys Ab Initio Biotherapeutics for US$12 Million.
10. PTC Therapeutics and Odylia Therapeutics have signed a deal to develop novel gene therapies in rare inherited retinal diseases.
11. Convelo Therapeutics Enters Into Collaboration and Option to Acquire Agreement With Genentech to Discover Novel Remyelinating Therapies.
12. Skyhawk Inks Deal With Genentech for Cancer and Neuro Drug Discovery.

Updates at Aagami: 

• Aagami CEO to visit India in September,2019.